Market Overview

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter

Share:
Related BIIB
Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform
Stiff Biosimilar Headwinds To Negatively Impact Amgen's Aging Drug Portfolio
Biotech Forum Daily Digest: Tesaro's Huge Week! Brexit Losses Gone, Spotlight On Applied Genetics Technologies (Seeking Alpha)
Related AMGN
Regeneron Is 'One Of The Stronger Growers In Biotech'
Stiff Biosimilar Headwinds To Negatively Impact Amgen's Aging Drug Portfolio
Strategic Dividend Dog Analysts Put MGA Tops For Summer (Seeking Alpha)

Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter.

Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter. Biogen Idec's trailing-twelve-month revenue is $5.64 billion.

Amgen (NASDAQ: AMGN) is expected to earn $1.80 per share in the September quarter. Amgen's trailing-twelve-month operating margin is 34.08%.

Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) is likely to earn $1.46 per share in the June quarter. Jazz Pharmaceuticals had $387.20 million in total cash for the latest quarter.

Celgene (NASDAQ: CELG) may earn $1.45 per share in the September quarter. Celgene's PEG ratio is 0.94.

Posted-In: Biotechnology Industry Highest EPS Estimates NASDAQ StocksTrading Ideas

 

Related Articles (AMGN + BIIB)

View Comments and Join the Discussion!